Trial reportPloS one2015
Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Immediate versus delayed dexamethasone implantation during vitrectomy for diabetic macular edema with secondary epiretinal membrane: A retrospective comparative study.The Journal of international medical research · 2026Article
- Mechanism and implications of advanced glycation end products (AGE) and its receptor RAGE axis as crucial mediators linking inflammation and obesity.Molecular biology reports · 2025Review
- Use of a multifocal electroretinogram to evaluate the therapeutic effect of a single intravitreal dexamethasone implant, OzurdexInternational journal of retina and vitreous · 2025Article
- The Effects of Slow-Release Dexamethasone in the Treatment of Diabetic Macular Edema.Pharmaceutics · 2025Review
- Does microperimetry have a role in monitoring visual function in patients with Behçet uveitis?BMC ophthalmology · 2024Observational
- Effectiveness of Suprachoroidal Injection of Triamcinolone Acetonide in Diabetic Macular Edema Following Pars Plana Vitrectomy Using a Modified Custom Microneedle.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Effects of Dexamethasone Intravitreal Implant on Multifocal Electroretinography in Diabetic Macular Oedema.Drug design, development and therapy · 2024Article
- Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema.Acta ophthalmologica · 2022Article
- Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema.International ophthalmology · 2021Article
- Assessment of Reinjection Numbers and Intervals for Diabetic Macular Edema Patients Who Received Dexamethasone Intravitreal Implants in Germany and Switzerland.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Response to comments on: Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema.Indian journal of ophthalmology · 2021Article
- Comments on: Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema.Indian journal of ophthalmology · 2021Article
- Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature.Pharmaceutics · 2020Review
- Efficiency analysis by mfERG and OCT of intravitreal injection with ranibizumab on diabetic macular edema.International journal of ophthalmology · 2020Article
- Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema.GMS ophthalmology cases · 2020Article
- Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema.BMC ophthalmology · 2019Article
- Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.BMC health services research · 2019Article
- Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study.International journal of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate changes in macular morphology and function after an intravitreal dexamethasone implant for diabetic macular edema (DME).
methodsTwenty-seven eyes in 27 treatment-naive patients affected by DME were treated with intravitreal Ozurdex® injections (IVOI) and followed up 12 months to evaluate morphological and functional changes by means of best-corrected visual acuity (BCVA), microperimetry (MP1), multifocal electroretinography (mfERG), pattern electroretinography (PERG) and spectral domain optical coherence tomography (SD-OCT).
resultsBoth BCVA and retinal sensitivity improved significantly at one month after the IVOI (p = 0.031 and p<0.0001, respectively). After five months, the improvement of BCVA remained statistically significant compared with baseline values (p = 0.022); retinal sensitivity improvement was statistically significant for up to four months after the IVOI (p = 0.059). Moreover, central macular thickness significantly decreased for up to four months. Interestingly, PERG and mfERG values did not change significantly for up to four months post-IVOI, but then began to worsen.
conclusionsIn eyes with DME, intravitreal dexamethasone implant determined morphological and functional improvement as soon as one month and for up to four months after the treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.